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Gastroesophageal reﬂux GWAS identiﬁes risk loci
that also associate with subsequent severe
esophageal diseases
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Gastroesophageal reﬂux disease (GERD) is caused by gastric acid entering the esophagus.
GERD has high prevalence and is the major risk factor for Barrett’s esophagus (BE) and
esophageal adenocarcinoma (EA). We conduct a large GERD GWAS meta-analysis (80,265
cases, 305,011 controls), identifying 25 independent genome-wide signiﬁcant loci for GERD.
Several of the implicated genes are existing or putative drug targets. Loci discovery is greatest
with a broad GERD deﬁnition (including cases deﬁned by self-report or medication data).
Further, 91% of the GERD risk-increasing alleles also increase BE and/or EA risk, greatly
expanding gene discovery for these traits. Our results map genes for GERD and related traits
and uncover potential new drug targets for these conditions.
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Esophageal adenocarcinoma (EA) is a fatal cancer with a highmortality rate1. Barrett’s esophagus (BE) is a precancerousconversion of the normal stratiﬁed squamous epithelium of
the distal esophagus to columnar epithelium2. Gastroesophageal
reﬂux disease (GERD), the frequent regurgitation of stomach acid
and bile, is the main risk factor for both BE and EA3–6.
GERD has a signiﬁcant socioeconomic burden due to its chronic
nature and high prevalence, with approximately 20% of the popu-
lation affected in western countries7. Expenditure on GERD is
enormous ($15–20 billion in the US alone in 20068), with spending
chieﬂy on medications. Medications that aim to alleviate or reduce
stomach acid secretion, include antacids, histamine–receptor
antagonists, and proton–pump inhibitors9. However, the efﬁcacy of
these medications varies considerably, and most people need pro-
longed or lifelong use. Furthermore, some have resistance to these
medications and, in some cases, medication is insufﬁcient and
surgical interventions are required9. Developing a better under-
standing of the etiology of GERD may lead to improved manage-
ment strategies, such as development of novel or repurposed
treatments, ultimately reducing the incidence of BE and EA.
Previous twin studies have shown a signiﬁcant genetic con-
tribution to the etiology of GERD, with an estimated heritability
of 30–40%10,11. We recently showed that GERD has a polygenic
basis, and estimated a high genetic correlation between GERD
and BE (rg= 0.77, SE= 0.24), and between GERD and EA (rg=
0.88, SE= 0.25)12. Thus in addition to improving our under-
standing of GERD, identifying genetic variants for GERD will
likely inform our understanding of the genetics of BE/EA.
However, previous work13 has not identiﬁed any genome-wide
signiﬁcant (P < 5 × 10−8) risk loci for GERD.
In this study, we perform a large genome-wide association
study (GWAS) meta-analysis of GERD, using population-based
studies from the UK, USA, and Australia. We aim to: (1) validate
the use of self-reported reﬂux medication as a proxy for GERD in
GWAS studies in order to increase statistical power; (2) identify
risk loci for GERD; (3) investigate the effect of GERD risk loci on
BE and EA; (4) identify the extent of genetic overlap between
GERD and its known risk factors (e.g., body mass index (BMI)) as
well as other complex traits; and (5) ﬁnd candidate drugs that
target signiﬁcant genes.
Results
GWAS of GERD. We ﬁrst undertook ﬁve GERD GWASs using
three GERD-related data sets from the UK biobank (UKBB) study
(ICD10, self-reported GERD, and use of GERD medication), the
QSkin study (heartburn and GERD medication use from Phar-
maceutical Beneﬁts Scheme (PBS) medical records), and from
self-report GERD from the 23andMe data set. Given the differ-
ences in phenotype deﬁnition across cohorts, we assessed the
similarity of the genetic effects across the cohorts by estimating
the LD-score genetic correlation (rg) between them. The rg values
were close to 1 in all cases (Fig. 1), except for QSkin where the
sample size was too small to allow reliable estimation of genome-
wide rg14. For all datasets (including QSkin), the correlation
between the logarithmic scale odds ratios (log ORs) of the peak
single nucleotide polymorphisms (SNPs) was also high (Supple-
mentary Data 1). The strong genetic correlations across the
GWAS results justiﬁed a meta-analysis of these data sets (UKBB
where the three phenotype deﬁnitions were ﬁrst combined and
run as one analysis to build the largest nonoverlapping
case–control set, 23andMe, and QSkin).
GERD is known to be strongly correlated with BE and EA12;
this was conﬁrmed in this study by estimating the genetic
correlation between GERD (from the above meta-analysis) and a
combined BE and EA dataset. The combined data set comprised
13,792 cases and 31,211 controls (Fig. 1), from a meta-analysis of
UKBB data (EA and BE cases vs. controls) and independent
cohorts from a previously published study15 (cohorts from
Barrett’s and Esophageal Adenocarcinoma Consortium [BEA-
CON], Cambridge, Oxford, and Bonn). The GERD-EA/BE
genetic correlation was 0.47 (SE= 0.03).
Using an estimated GERD prevalence of 12% among
Europeans16, we calculated the GERD SNP heritability (h2) on
the liability scale as 11.3% (SE= 0.004) from the combined
GERD GWAS meta-analysis (altering the speciﬁed prevalence
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Fig. 1 Genetic correlation between phenotypes. The lines with two arrows show the genetic correlation (standard error in brackets) from the result of LD-
score regression rg, genetic correlation estimates from the LD score regression. There is sample overlap between UKBB cases with either ICD10, self-report
or medicine based GERD and the numbers do not add up to the total UKBB samples size. As the correlation is computed as the estimated covariance
divided by product of the estimated standard error of the two traits, the correlation estimates may be slightly >1 when the correlation is high. NA* sample
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does not change the SNP heritability appreciably—for example, at
a prevalence of 25% h2 only changes to 14.3%). The LD-score
intercept for this combined analysis was 1.04 (SE= 0.008),
indicating no strong evidence for inﬂation due to population
structure or sample overlap14. Deﬁning statistically independent
SNPs based on a conditional approach in GCTA17 (see Methods),
25 SNPs were associated with GERD in our meta-analysis,
representing 25 statistically independent associations (Tables 1
and 2). A Manhattan plot of the GERD GWAS meta-analysis is
shown in Fig. 2, with the Quantile–Quantile plot (QQ plot)
shown in Supplementary Fig. 2.
Gene-based tests (Supplementary Data 5) were conducted using
the MAGMA18 software based on the per-SNP GWAS summary
results for GERD. We identiﬁed 49 genes that are associated with
GERD after Bonferroni correction for 19,427 genes tested (P <
2.57 × 10−6); although many were found by per-SNP tests, 20
were only signiﬁcant using gene-based tests (Table 3). We also
conducted analysis using MetaXcan19, a gene-based approach that
uses gene expression derived from the GTEx project data and the
association summary statistics from the GERD GWAS to test the
association between genes and GWAS phenotypes (Supplemen-
tary Data 6). To reduce multiple testing for our primary analysis
we did not test every GTex tissue; we only tested three relevant
esophageal tissue types (esophageal gastroesophageal junction,
esophagus mucosa, and esophagus muscularis) as well as whole
blood. The total number of genes to test for four tissues is 23,836
(3707, 6944, 6471, and 6714 for each tissue, respectively), resulting
in Bonferroni-corrected signiﬁcance threshold of 2.1 × 10−6.
Using MetaXcan, we identiﬁed three genes (CTD-2228K2.5,
CACYBP, and EXOC3) that were not signiﬁcant in single SNP
or MAGMA gene-based testing. We also conducted a secondary
analysis examining all 44 GTex tissues, with a more stringent
multiple testing threshold to reﬂect the larger number of tests
conducted: in this analysis we identiﬁed 5 additional loci not
signiﬁcant in the earlier analysis steps.
The effect of GERD SNPs on BE/EA. Since GERD is a risk factor
for EA and BE, we investigated whether our signiﬁcant GERD
SNPs were also associated with BE and EA. In practice, many BE
or EA cases also have GERD and just for the purposes of assessing
the effect of “GERD only” derived genes on BE/EA (our main
GWAS to determine GERD loci does include all GERD cases,
including those who have BE and/or EA), we re-ran the GERD
GWAS after excluding BE/EA cases and their relatives (pi-hat >
0.2). In all, 19 independent signiﬁcant GERD risk SNPs were
identiﬁed using GCTA-COJO algorithm20. We found 7 of the 19
GERD SNPs were also associated with BE at P < 0.05 (binomial
probability of this happening by chance P= 1.8 × 10−6), with
four associated at Bonferroni-corrected P < 0.05/19, and 17 with
the same direction of effect (here we considered only the 19 SNPs
signiﬁcant when the GERD GWAS was conducted with BE/EA
samples excluded). We found 6 of the 19 GERD SNPs were
associated with EA at P < 0.05 (binomial probability of this
happening by chance P= 2.3 × 10−5), with two at Bonferroni-
corrected P < 0.05/19, and 17 with the same direction of effect
(Supplementary Data 8). In a previous study of BE/EA we
identiﬁed 14 genome-wide signiﬁcant SNPs15; half of these were
associated in our GERD GWAS here, with 2 reaching genome-
wide signiﬁcance (Supplementary Table 9). Although our case
numbers were lower for BE/EA compared with GERD, resulting
in fewer strongly signiﬁcant loci for BE/EA (Tables 1 and 2), the
GERD-associated SNPs showed good concordance in terms of
their estimated effect on BE/EA; the correlations between the
estimated log(OR)s for GERD SNPs vs. BE/EA, BE and EA were
0.52 (P= 4.61 × 10−4), 0.42 (P= 2.65 × 10−3), and 0.41 (P= T
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3.38 × 10−3), respectively (Supplementary Fig. 1c–e). Many of the
SNPs in Tables 1 and 2 have EA/BE P-values in the range 0.05 to
1e−4, corresponding to chi-squared variables ranging from 3.84
to 15.13. Since the genome-wide signiﬁcance threshold (P= 5e
−8) is 29.7 on the chi-squared scale, for these SNPs we might
expect to need BE/EA sample sizes that are between ~2 and ~8
times bigger than are currently available.
GERD-related traits. We performed a look-up using the LD
hub21 database to evaluate whether GERD is genetically corre-
lated with other phenotypes. The highest genetic correlations
were with education (years of schooling), depression, and BE/EA
(Supplementary Data 2). We conﬁrmed the depression result
using a recently published larger depression GWAS22 and
obtained a very similar result (rg= 0.52, SE= 0.03). Similarly
based on recent GWAS for BMI23,24, education24, and height23,
correlation estimates were (rg= 0.35, SE= 0.02), (rg=−0.43, SE
= 0.02), and (rg=−0.12, SE= 0.02), respectively (Fig. 3).
Phenome-wide association. To further investigate each of
GERD-associated SNPs in Tables 1 and 2 against an extensive
record of phenotypes, we performed a Phenome-wide association
scan (PheWAS) to evaluate the association of our GERD SNPs
using the Gene-ATLAS25 repository (http://geneatlas.roslin.ed.ac.
uk/phewas/). Many are associated (P < 5 × 10−8) with a range of
complex traits (Supplementary Data 3). In total, 13 of the peak
SNPs are strongly associated with BMI or related traits. Two
SNPs rs7763910 and rs9266237 are associated with malabsorp-
tion/celiac disease. Five of the GERD-associated peak SNPs
(rs1937450, rs3106209, rs10242223, rs12706746, and rs967823)
are associated with cigarette smoking in Gene-ATLAS.
Putative drug targets. We used the online Open-targets drug
database (www.targetvalidation.org) to assess if any of the genes
implicated in our GERD GWAS are potential drug targets. For
each locus in Tables 1–3, we used evidence from eQTL databases,
plus gene-based tests in MAGMA and MetaXcan to identify
putative target genes of the peak SNPs. We identiﬁed seven genes
targeted by drugs currently in use or in clinical trials (Table 4).
Three of these are existing drug targets for reﬂux, BE, or eso-
phageal cancer. The remaining four are drug targets for cancer or
obesity and may constitute interesting drug targets for reﬂux and
related traits. While we cannot guarantee that the named genes in
Table 4 are the correct (or sole) target genes, in each case there is
at least some evidence for the named gene. Further details of the
drugs used for these genes are in Supplementary Data 4.
Discussion
Although GERD has been previously established to be heritable,
in previous reﬂux gene-mapping efforts the small effect sizes were
an insurmountable problem. In our study, combining across
phenotype deﬁnitions within UKBB (self-report, ICD10, medi-
cation records) and across cohorts was a major factor in our
success. For example, a previous GERD GWAS found no
genome-wide signiﬁcant loci13 and an online convenience ana-
lysis of gastroesophageal reﬂux (gord)/gastric reﬂux in UKBB (N
= 19,242 cases, http://geneatlas.roslin.ed.ac.uk/trait/?traits=638)
found only two loci (the peak SNPs at these are correlated with
the two MHC loci we identify here)—these results have not been
published. We identiﬁed 25 independent loci in SNP-based tests
and a further 23 (20 from MAGMA, 3 from MetaXcan) using
gene-based tests.
Several of the genes implicated by our analysis are drug targets,
either for drugs already used in GERD, BE, or EA, or for drugs
currently used for other conditions. In the latter case, these drugsT
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should be re-evaluated for possible use with GERD. A subset of
the GERD genes also have an effect on BE and/or EA, and are
therefore possible drug targets for these conditions: among the
putative drug targets in Table 4, the peak SNPs in two genes
(EPHB1 and CCKBR) show a larger effect (odds ratio) on BE/EA
than they do on GERD. Two further genes (MST1R and CDK2)
show a similar effect size for BE/EA as for GERD (although the P-
values are only 0.05 < P < 0.1 due to the smaller sample size for
BE/EA), whilst three (PDE4B, DYPD, and LAMA2) show no
association with BE/EA. In addition to the information in
Table 4, DPYD has been reported to play a role in chemosensi-
tization in esophageal cancer26. For the locus at rs11171710
(chr12:56368078, putative gene CDK2) mapping the target gene is
difﬁcult as there are many possible target genes in the region.
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Fig. 2 Manhattan plot for GERD from meta-analysis of 81,077 GERD cases and 307,284 controls. The x-axis shows genomic position (chromosome 1–22)
and the y-axis shows the log10 (P-value) of the SNP association. The threshold for genome-wide signiﬁcance is set at P= 5.0 × 10−8 (the red-dotted
horizontal line)
Table 3 Additional GERD genes identiﬁed via gene-based tests
Gene Gene interval Top SNP SNP-P Gene-P eQTL PheWAS
KIAA1522 1:3,320,749–33,240,571 rs61798840 2.27 × 10−5 1.61 × 10−6 Obesity (6.5 × 10−6)
PDE4B 1:66,258,193–66,840.262 rs1937450 1.63 × 10−8 7.01 × 10−9 Obesity (3.0 × 10−9)
RABGAP1L 1:174,128,552–174,964,445 rs333423 4.70 × 10−7 6.04 × 10−9 1.7 × 10−30 MDD (2.8 × 10−6)
MST1R 3:49,924,435–49,941,311 rs7613875 4.89 × 10−8 6.33 × 10−8 7.9 × 10−12 BMI(6.9 × 10−33
EDU(3.6 × 10−28)
RBM5 3:50126341–50156397 rs7613875 4.89 × 10−8 5.28 × 10−8 9.0 × 10−60 BMI(6.9 × 10−33
EDU(3.6 × 10−28)
SEMA3F 3:50192562–50226508 rs7613875 4.89 × 10−8 3.49 × 10−7 9.2 × 10−6 BMI(6.9 × 10−33
EDU(3.6 × 10−28)
MAGI1 3:65,339,200–66,024,511 rs9815340 2.36 × 10−6 2.06 × 10−6
LCORL 4:17,844,839–18,023,483 rs1993638 1.06 × 10−6 1.73 × 10−6
SNX2 5:122,110,691–122,170,234 rs7707685 1.26 × 10−7 1.30 × 10−6 NA
SGCD 5:155,462,147–156,194,799 rs56785833 2.13 × 10−6 1.88 × 10−6 2.4 × 10−18
LAMA2 6:129,204,286–129,837,711 rs9492232 5.97 × 10−7 2.67 × 10−7 NA Obesity (9.4 × 10−9),
Smoking (3.4 × 10−6)
SNX10 7:26,331,515–26,413,949 rs12700707 2.48 × 10−6 2.32 × 10−7 NA
VIPR2 7:158,820,866–158,937,649 rs2730263 4.95 × 10−7 1.81 × 10−6 4.3 × 10−17 Smoking (4.7 × 10−5)
LMX1B 9:129,376,722–129,463,311 rs10760444 9.01 × 10−7 1.87 × 10−7 NA Obesity (1.3 × 10−8)
ACAD10 12:112,212,3857–112,194,911 rs597808 1.33 × 10−8 2.52 × 10−7 NA Obesity (1.3 × 10−23)
Smoking(1.1 × 10−10)
YLPM1 14:75,230,025-75,304,013 rs17183201 2.08 × 10−6 4.98 × 10−7 NA
SPG7 16:89,574,802–89,624,174 rs57696383 2.50 × 10−7 8.86 × 10−7 1.4 × 10−21 Height(2.1 × 10−16),
Obesity (1.2 × 10−12)
SETBP1 18:42,258,849–42,648,475 rs2028653 9.73 × 10−6 1.18 × 10−6 NA Obesity (1.6 × 10−4),
Height (1.5 × 10−5)
DCC 18:49,866,542–51,062,273 rs56796226 8,62 × 10−6 4.98 × 10−10 2.6 × 10−5 MDD (1.0 × 10−8), EDU (1.1 × 10−6),
Height (1.2 × 10−5)
TCF4 18:52,889,562–5,330,322 rs77262239 1.02 × 10−6 8.99 × 10−8 NA MDD (4.0 × 10−6)
Gene-based test results from MAGMA software. Regions which already exceeded per-SNP genome-wide signiﬁcance in Tables 1 and 2 are not shown here. The gene interval in the form Chromosome:
start–stop bp is shown mapped to hg19. Top SNP refers to the SNP with the lowest P-value in the region, with SNP-P the P-value for that SNP. Gene-based-P is the gene-based P-value. The eQTL column
shows the lowest P-value for testing the correlation between gene expression and genotype of the top SNP in 44 GTEx tissues. PheWAS column shows any strong associations for the top SNP with any
of BMI, obesity, education, major depression, height, and smoking. The PheWAS results were retrieved from the online Open-Targets database https://genetics.opentargets.org. They are listed in the
PheWAS column alongside its P-value. More detailed eQTL and PheWAS results are in Supplementary Table 14.
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rs11171710 is an eQTL for multiple nearby genes (SUOX, RPS26,
and RAB5B), with SUOX also signiﬁcant in our MetaXcan19
analysis (Supplementary Data 6). Although there is no eQTL
effect on CDK2, the peak SNP is 1.5 kb from CDK2. CDK2 is a
key cell cycle regulator which inactivates phosphorylation of the
RB1 (pRb) tumor suppressor family27. Previous work supports
the case for the relevance of CDK2 because proliferation of EA
cells is decreased when CDK2 is downregulated28.
One of the SNPs (rs11901649, chr2:21250223) that is asso-
ciated with GERD at genome-wide signiﬁcance is located in an
intron of the APOB gene. This variant is strongly associated with
high-cholesterol levels in the UKBB data set (Gene ATLAS P=
5.26 × 10−89), suggesting a potential link between cholesterol
levels and GERD risk. A previous observational study also found
an association between cholesterol and GERD29. This variant was
also found to be associated with BE/EA (P= 1.03 × 10−7). The
association over APOB is 380 kb from a previously reported BE
signal30 over the GDF7 gene, which also shows some signal for
GERD; the peak SNP (rs3072) near GDF7 has no correlation with
rs11901649 (r2= 0.01), but it has a suggestive level of association
with GERD (P= 1.68 × 10−7).
We identiﬁed two independent GERD risk loci on chromo-
some 19, both of which are also associated with BE/EA. The ﬁrst
locus is located near CRTC1 (rs12974777, chr19:18765663), is an
established risk locus for EA31. The second locus is located ~400
kb away from CRTC1 (rs1363119), nearby GDF15 and PGPEP1.
Although rs1363119 is not an eQTL in GTEx, tissue and plasma
expression levels of GDF15 associate with BE and EA, with
GDF15 plasma levels inﬂuenced by the use of nonsteroidal anti-
inﬂammatory drugs that are known to affect esophageal
adenocarcinogenesis32.
Previous GWASs on EA and BE found genetic associations
with rs9257809 (chr6:29356331) in the MHC region15. In the
present study, we found three independent associations with
GERD in this region; rs7763910 (chr6:26472655), rs9266237
(chr6:31325521), and rs114863007 (chr6:34729158). Although
the BE/EA SNP rs9257809 and the GERD SNP rs9266237 are 2
Mbp apart in the MHC region, they are in modest LD (r2= 0.12).
SNP rs9266237 showed no association (P= 0.19) in our EA/BE
dataset. We also found rs9266237 was strongly associated with
celiac disease (P= 1.31 × 10−185, Supplementary Data 3).
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Fig. 3 Traits with signiﬁcant genetic correlation with GERD. Vertical axis
displays genetic correlation from LD-score regression. Error bars denote
±1 standard error
Table 4 Putative drug target genes from GERD GWAS
Gene chr Start, stop Evidence for this
particular gene
Drug(s) Currently
used for
GERD/EA/BE
Highly expressed tissues
(TPM)
CCKBR 11 6,280,841–6,293,363 Peak SNP rs12792379 is an eQTL
for CCKBR
PROGLUMIDE,
NETAZEPIDE
Yes Stomach (40), brain frontal
cortex (22), brain cortex (22),
brain cerebellum (22), brain
cerebellar hemisphere (22)
EPHB1 3 134,514,099–134,851,891 Peak SNP rs60716777 is
between EPHB1 and KY; this SNP
is eQTL for KY, although
noteworthy because EPHB1 is
esophageal cancer drug target
VANDETANIB Yes Brain-cerebellar hemisphere
(33), brain-cerebellum (23),
brain-caudate (10), brain-
putamen (9.5), cells-EBV (9.3)
CDK2 12 56,360,556–56,366,568 See paragraph in discussion
section
Multiple Yes EBV (64), esophagus-
muscularis (32), lung (32),
ovary (32), skin (28)
DPYD 1 97,543,300–98,386,615 Peak SNP rs7552188 is an eQTL
(esophageal mucosa) for DPYD
ENILURACIL No Transformed ﬁbroblasts (40),
lung (27), whole blood (20),
spleen (19), ovary (19)
PDE4B 1 97,543,300–98,386,615 Signal wholly over PDE4B;
Signiﬁcant MAGMA result
Multiple No Brain-spinal cord (29), brain-
nucleus (17), brain-
hypothalamus (14), brain-
frontal (14), brain-cortex (14)
MST1R 3 49,924,436–49,941,306 Peak SNP rs7613875 is an eQTL
(esophagus mucosa) for MST1R;
signiﬁcant MetaXcan and
MAGMA result
NARNATUMAB, MK-
8033, MGCD-265
No Brain-spinal cord (30), brain-
nucleus (17), brain-substantia
(16), brain-frontal (16),
spleen (16)
LAMA2 6 129,204,286–129,837,710 Signal wholly over LAMA2;
Signiﬁcant MAGMA result
OCRIPLASMIN No Ovary (121), nerve-tibial (91),
fallopian tube (74),
transformed ﬁbroblasts (72),
cervix-endocervix (55)
Two further genes (KCNB2 on chromosome 8, SLC9A3 on chromosome 5) are drug targets, but we have not listed them in Table 4 as the link from the peak SNP to the putative target gene was weaker
than for those in Table 4 (e.g., there are several equally likely candidate genes in the region). The top ﬁve expressed genes obtained from GTEx portal (https://gtexportal.org/home/gene, TPM is
transcripts per kilobase million).
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Several of the top GERD SNPs are associated with traits which
are risk factors for GERD (e.g., obesity and smoking). We found
strong genetic correlations between GERD and BMI, education,
depression, neuroticism, and cigarette smoking. Disentangling the
effects of these risk factors is difﬁcult although it is likely that
some of these effects are mediated via the GERD risk factor BMI;
there are known genetic correlations between education level and
BMI33, while a recent depression study suggested there is a causal
link between BMI and depression22.
This study has some limitations. First, because GERD cases
were determined using various sources (ICD10 code, self-
reported questionnaires, medical history, and medicine use), the
phenotypic deﬁnition may not be uniform among all the parti-
cipating studies. However, the very high-genetic correlation (rg >
0.9; Fig. 1) between the different GERD phenotypes suggests this
is not a major issue. Of particular note, we observed a high
genetic correlation (rg= 0.94, SE= 0.018) between GERD phe-
notypes deﬁned through ICD10 and self-reported medication use,
showing that the later can be used as a reliable proxy for ICD10-
based GERD diagnosis to increase power. To further conﬁrm that
using reﬂux medicine can be robustly deﬁned as a reﬂux phe-
notype, we undertook GWAS on individuals who took reﬂux
medicine but who did not self-report as having reﬂux, and who
do not have an ICD10 medical record of reﬂux. LD regression
was then performed to assess the correlation of this GWAS result
with self-reported reﬂux and ICD10. LD regression analysis
indicates a 0.93 (SE= 0.042) and 0.91 (SE= 0.03) correlation
with self-reported GERD and ICD10, respectively. The correla-
tion plot between top GWAS results from GERD medicine use
with self-reported GERD and ICD10 are shown in Supplementary
Fig. 1f, g. The very high genetic correlation of individuals that use
reﬂux medicine with individuals that self-report or who have an
ICD10 record of GERD indicates that the use of reﬂux medication
is an appropriate proxy phenotype for classifying an individual as
having GERD. Second, although we have attempted to incorpo-
rate information on eQTL, for many loci the target gene or genes
remains to be determined. While several of the genes highlighted
by our GWAS are drug targets, further work will be required to
determine if any of the other genes constitute suitable drug targets
which can be exploited in the future. Thirdly, although the fact
that many of the identiﬁed GERD loci are associated with obesity
conﬁrms the important role of obesity in GERD risk, when we
conducted a formal pathway analysis based on the GERD GWAS
meta-analysis, no pathways remained signiﬁcant following cor-
rection for multiple testing (Supplementary Data 7). Finally,
although these results may yield putative new drug targets for
GERD/BE/EA via repurposing of drugs for other conditions,
clearly there is a long way to go from such initial indications to
efﬁcacious drug design.
In conclusion, we present here the ﬁrst successful GWAS
reporting genome-wide signiﬁcant genetic loci for GERD sus-
ceptibility. Several of our identiﬁed hits are related to established
GERD risk factors, BMI, and smoking, with approximately half of
them showing associations with BE and EA. Three of the target
genes are already GERD/EA/BE drug targets and four others are
drug targets for other diseases and as such would be very inter-
esting to investigate for potential medication repurposing for
reﬂux, BE, or EA. Future studies are warranted to further explore
the biological signiﬁcance of these risk loci, and how they may be
useful to inform clinical practice and drug development.
Methods
UKBB cohort. UKBB is a cohort study of approximately 500,000 people aged
between 40 and 69 years that reside in the UK. All individuals in the UKBB cohort
provided informed written consent, and the study was approved by the National
Research ethics Service Committee, North West Haydock. All procedures in the
research were undertaken in accordance with the World Medical Association
Declaration of Helsinki ethical principles for medical research. The Affymetrix UK
BiLEVE Axiom array was used to genotype 487,409 participants. Totally, 7.6
million variants with a minor allele frequency (MAF) > 0.01 and HWE P-value >
1 × 10−6 were successfully imputed. A full description of the UKBB can be found in
the report by Bycroft et al.34. For this study, we focused solely on 438,870 indi-
viduals who were genetically similar to individuals of white-British ancestry based
on ancestral principal components (see ref. 35).
The GERD phenotype data was collated across the following UKBB data ﬁelds:
self-report (ﬁeld ID: 20002—Noncancer illness code, self-reported Medical
conditions), ICD10 (41202—main diagnoses in ICD10, 41204—secondary
diagnosis in ICD10), ICD9 (41203—main diagnoses in ICD9, 41205—secondary
diagnosis in ICD9), OPCS (41200—main operative procedures; 41210—secondary
operative procedures) (Supplementary Table 1) and treatment/medicine
(Supplementary Table 3). Each category was regarded as an indicator of GERD
status. The number in each category is summarized in Supplementary Table 4.
Individuals who did not have any disorders in their upper digestive system were
deﬁned as controls (Supplementary Table 2). In total, there were 68,535 cases and
250,910 controls based on the criteria of a GERD case having at least one of the
GERD-positive indicators from above. The average age of the cases is 59.00 (SD=
7.48). The overall average age for UKBB samples is 56.54 (SD= 8.09).
In UKBB BE cases were deﬁned by medical record ICD10 (International
Classiﬁcation of Diseases). The data were extracted from the UKBB Field ID 41202/
41204 (ICD10 main and secondary diagnosis) using code K227 (Supplementary
Table 5). EA was deﬁned using ICD10 in the UKBB ﬁeld 40006 (cancer registry)
with codes starting with symbol “C15”. The cancer tumor histology code in UKBB
Field ID 40011 was used to reﬁne the adenocarcinoma cancer type (Supplementary
Table 6). The number of BE and EA cases was 2831 and 568, respectively. The
average age of the BE cases is 60.42 (SD= 6.60). The average age of the EA cases is
62.43 (SD= 5.43). For the BE and EA analysis, 250,910 controls were selected
among the people who did not have any disorders in their upper digestive system.
23andMe cohort. As we previously reported12, 23andMe supplied GWAS sum-
mary statistics based on 8743 GERD cases and 43,932 controls of primarily (>97%)
European ancestry. All participants provided informed consent under a research
protocol that was approved by the AAHRPP-accredited institutional review board,
Ethical and Independent Review Services, USA. Genotyped SNPs were ﬁltered
using HWE P-value > 1 × 10−20, MAF > 1%. Cases self-reported whether they have
ever been diagnosed by a doctor with heartburn, acid reﬂux or acid reﬂux disease,
or were treated with medicines for acid reﬂux/heartburn. Controls were individuals
who did not report any symptoms of heartburn, acid reﬂux, or the use of medi-
cations to treat acid reﬂux.
QSkin health study cohort. The QSkin cohort36 comprises 43,794 participants
aged between 40 and 69 years from Queensland, Australia. The work outlined here
was approved by the Human Research Ethics Committee of the QIMR Berghofer
Medical Research Institute. QSkin participants provided written informed consent
to take part in the project. Totally, 17,220 samples were genotyped using Illumina
GSA array. GERD cases were deﬁned as individuals who self-reported heartburn
and took one or more reﬂux medications, identiﬁed by linkage with the PBS
database which captures the use of all prescription medications that are subsidized
by the Australian Government (Supplementary Table 7). Individuals whose self-
report and medication statuses conﬂicted were removed. In all there were 2987
GERD cases, together with 10,169 controls (individuals without heartburn).
Genotyped SNPs were ﬁltered using the following criteria; GenTrain > 0.6,
HWE P-value > 1 × 10−6, and MAF > 1% using GenomeStudio/BeadStudio and
PLINK (version1.9)37. In total, 189,387 SNPs failed genotyping quality control
leaving 496,695 SNPs for imputation. Samples with >5% missing data were
removed. Genotype phasing was performed using Eagle 238 and imputation was
conducted using minimac version 339 through the University of Michigan
Imputation Server. SNPs with MAF > 0.01 and imputation quality score >0.3 were
taken forward for association analysis.
Cohort studies for BE and EA. We obtained GWAS summary statistic results for
BE and EA from the following ﬁve GWASs of European, North American, and
Australian participants30,40,41: (1) UKBB; (2) The Barrett’s and Esophageal Ade-
nocarcinoma Consortium (BEACON) study; and studies from (3) Bonn; (4)
Cambridge; and (5) Oxford. Informed consent was obtained for all participants for
all ﬁve studies, and ethics approval was obtained from the ethics boards of every
participating institution. The total numbers of cases and controls for BE are 8998
and 19,247, respectively. The total numbers of cases and controls for EA are 4680
and 15,751, respectively (Supplementary Table 8). We combined BE and EA as one
phenotype (BE/EA) as BE is the premalignant precursor of EA and has a very high-
genetic correlation with EA42.
Association testing for UKBB cohort. In UKBB we performed SNP-association
testing for GERD using a linear-mixed model implemented in the program BOLT-
LMM v2.343 to account for cryptic relatedness. Recruitment age, genetic sex, and
the ﬁrst ten principal components were ﬁtted as covariates. We used a sparse set of
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360,087 genotyped SNPs spanning the autosomes to derive the Bayesian mixture
prior which was subsequently used to model the SNP associations.
Due to the low prevalence of BE/EA which may result in inﬂated type I error
rates in BOLT-LMM43, a logistic model implemented in PLINK44 version 1.90b
was used for the UKBB BE/EA GWASs. Because the logistic model assumes
individuals are unrelated, related individuals were identiﬁed based on identity by
descent status estimated using autosomal markers, and if two individuals were
related (pi-hat > 0.2), one was removed preferentially from the control set. The ﬁnal
number of BE and EA cases becomes 2667 (=2831–164) and 549 (=168–19). The
ﬁnal number of controls for BE and EA becomes 221,787 (=250,910–29,123) and
221,816 (=250,910–29,094), respectively. Sex and recruitment age were ﬁtted as
covariates.
Meta-analysis. GWAS results for GERD from the UKBB were combined with
those from 23andMe and QSkin using a ﬁxed-effects meta-analysis in METAL45
(2011-03-25 version) using SNP effect sizes and their standard errors. We con-
verted regression coefﬁcients obtained on the quantitative scale from BOLT-LMM
into the equivalent log(OR) from logistic regressions for case–control studies using
the following formula46: log(OR) ~=beta/(mu × (1−mu)), where beta is regres-
sion coefﬁcient of the SNP from BOLT–LMM and mu is the proportion of cases in
the GWAS. At the completion of the meta-analysis, we used LD-score regression to
estimate if there was any inﬂation due to uncorrected for population stratiﬁca-
tion14. To correct for the slight inﬂation seen, each SNP’s chi-squared value was
divided by the intercept (1.04) from LD-score regression results to obtain a ﬁnal P-
value
To investigate the association of GERD loci with BE/EA, the BE/EA GWAS
results obtained from the UKBB analysis were meta-analyzed with four other
datasets15 using a ﬁxed-effect meta-analysis in METAL45 (Supplementary Table 8).
Since the number of individuals with BE/EA in UKBB was very small, the number
of controls was set to four times the number of cases, which were randomly
selected from the individuals with no reported (ICD10) upper digestive system
problems. To avoid overlapping samples between GERD and BE/EA datasets, we
re-ran the GERD GWAS after removing any BE/EA individuals and their relatives
(pi-hat > 0.2) from the UKBB GERD dataset.
Deﬁning independent genome-wide signiﬁcant SNPs. We used the stepwise
model selection procedure in GCTA-COJO20 (GCTA software version 1.26) to
perform conditional and joint association analysis to identify independent genome-
wide signiﬁcant SNPs. GCTA-COJO uses GWAS summary results, with LD esti-
mated from a reference sample comprising 5000 randomly selected people of
white-British ancestry from UKBB. For each index SNP, SNPs within a 10
megabase region (window 10Mb) were considered for conditioning. We report
only SNPs where both the joint and raw P-values were <5 × 10−8. The minimum
MAF was set at 1%.
Bivariate LD score regression. We used LD score regression14 to quantitatively
measure the genetic correlation between traits; this approach takes into account
any sample overlap between the input GWASs. We also performed a look-up on
the publicly available LD hub21 database to evaluate whether GERD is genetically
correlated to other phenotypes.
Gene-based tests. Gene-based tests were conducted with MAGMA18 based on the
per-SNP GWAS summary results for GERD (Supplementary Data 5). We used
MAGMA version 1.07 and gene annotations from NCBI Human version 37. We
also conducted analysis using MetaXcan19, a gene-based approach that uses gene
expression derived from the GTEx Project data and association summary statistics
from GERD GWAS to test the association between genes and GWAS phenotypes
(Supplementary Data 6). To reduce multiple testing in our primary analysis we
only tested four tissues types; three relevant to GERD (Esophageal Gastro-
esophageal Junction, Esophagus_Mucosa and Esophagus Muscularis), plus a more
generic tissue type with large sample size (whole blood). The total number (23,832)
of genes in these 4 tissues was used to determine threshold P-value 2.1E−06
(=0.05/23,832) of signiﬁcant genes. We also conducted a secondary analysis in all
44 GTEx tissues where we corrected for the total number of genes tested across all
tissues (Bonferroni signiﬁcance threshold 0.05/204,388) For all gene-based tests, we
used per SNP P-value from the GERD GWAS result after correction for the LD-
score intercept (1.04).
Pathway-based tests. We performed pathway-based enrichment analyses using
the GERD meta-analysis results in DEPICT47. DEPICT uses the likelihood of
involvement of genes in each gene set, based on coregulation of gene-expression
data. The preconstituted 14,462 gene sets are used to assess whether candidate
genes from the GWAS results are signiﬁcantly enriched in these gene sets.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.
Data availability
GWAS summary statistics from the meta-analysis of GERD in UK Biobank and QSKIN
can be downloaded from URL (https://doi.org/10.6084/m9.ﬁgshare.8986589). GWAS
summary statistics for the 23andMe samples are available via direct request to 23andMe
(dataset-request@23andMe.com; a data transfer agreement is required). The raw genetic
and phenotypic UK Biobank data are available from http://www.ukbiobank.ac.uk/.
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